In the latest National Comprehensive Cancer Network ALL guidelines (NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers), CA19-9, CEA, and AFP were recommended as tests to diagnose ICC [29], while serum PIVKA-II levels were not mentioned. This evidence concerns the gene AFP and intrahepatic cholangiocarcinoma.